Lexicon Pharmaceuticals (NASDAQ:LXRX) released its earnings results on Thursday. The biopharmaceutical company reported $2.11 EPS for the quarter, beating the Zacks’ consensus estimate of $1.31 by $0.80, Fidelity Earnings reports. The firm had revenue of $294.45 million during the quarter, compared to analysts’ expectations of $12.00 million. The company’s revenue for the quarter was up 4124.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.26) EPS.
NASDAQ:LXRX traded down $0.36 during trading hours on Friday, reaching $3.52. 1,316,800 shares of the company traded hands, compared to its average volume of 1,292,482. The business’s 50-day moving average price is $3.52 and its two-hundred day moving average price is $4.21. Lexicon Pharmaceuticals has a 1 year low of $1.13 and a 1 year high of $9.15. The stock has a market capitalization of $419.77 million, a P/E ratio of -3.09 and a beta of 0.95.
In other news, CEO Lonnel Coats bought 37,000 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The shares were bought at an average cost of $1.35 per share, for a total transaction of $49,950.00. Following the completion of the transaction, the chief executive officer now owns 87,695 shares of the company’s stock, valued at $118,388.25. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Christopher J. Sobecki bought 25,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The stock was purchased at an average price of $2.55 per share, for a total transaction of $63,750.00. Following the completion of the transaction, the director now directly owns 112,493 shares of the company’s stock, valued at approximately $286,857.15. The disclosure for this purchase can be found here. Insiders bought 255,749 shares of company stock worth $578,510 over the last 90 days. Company insiders own 6.40% of the company’s stock.
A number of research firms have recently commented on LXRX. Citigroup cut Lexicon Pharmaceuticals from a “buy” rating to a “neutral” rating and raised their target price for the company from $3.00 to $4.00 in a research note on Friday. Gabelli upgraded Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 target price for the company in a research note on Wednesday, September 11th. BidaskClub cut Lexicon Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 5th. ValuEngine upgraded Lexicon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 2nd. Finally, G.Research upgraded Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. One analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $6.45.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Featured Article: Fundamental Analysis
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.